OSU-53
OSU-53 is an orally active AMPK activator and mTOR inhibitor, with an IC50 of 0.3 μM for AMPK, an EC50 of 2-5 μM for AMPK, and an IC50 of 8.23 μM for mTOR. OSU-53 inhibits the Akt signaling pathway, directly activates AMPK by binding to its autoinhibitory domain, reduces IKKβ-mediated phosphorylation of Foxo3a, blocks Akt-mediated phosphorylation of MDM2, and promotes the nuclear localization and stabilization of Foxo3a, while directly inhibiting mTOR. OSU-53 inhibits epithelial-mesenchymal transition (EMT), induces epithelial phenotype, suppresses invasion and metastasis, induces autophagy, inhibits the activation of ERK and Akt, reduces the secretion of nitric oxide and proinflammatory cytokines, and inhibits the migration of MDSC; at high doses, it induces MDSC apoptosis, attenuates the immunosuppressive effect of MDSC, reduces MDSC levels, and blocks incision-induced mechanical hyperalgesia. OSU-53 can be used in studies related to breast cancer, prostate cancer, thyroid cancer, melanoma and postoperative pain.
For research use only. We do not sell to patients.
- CAS No.: 1290069-19-0
- Formula: C25H24F3N3O6S2
- Molecular Weight:583.60
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All AMPK Isoforms
More
Biological Activity
Description
|
AMPK 0.3 μM (IC50) |
AMPK 2-5 μM (EC50) |
mTOR 8.23 μM (IC50) |
Akt |
IKKβ |
FOXO3a |
MDM2 |
MDSC |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | IC50 |
5 μM
|
Antiproliferative activity against human MCF-7 cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Antiproliferative activity against human MCF-7 cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
24994714 |
| MDA-MB-231 | IC50 |
7.5 μM
|
Antiproliferative activity against human MDA-MB-231 cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Antiproliferative activity against human MDA-MB-231 cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
24994714 |
| MDA-MB-468 | IC50 |
5 μM
|
Antiproliferative activity against human MDA-MB-468 cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Antiproliferative activity against human MDA-MB-468 cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
24994714 |
| 4T1 | IC50 |
6 μM
|
Antiproliferative activity against mouse 4T1 cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Antiproliferative activity against mouse 4T1 cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
24994714 |
| LNCaP | IC50 |
9 μM
|
Antiproliferative activity against human LNCaP cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Antiproliferative activity against human LNCaP cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
24994714 |
| DU-145 | IC50 |
8 μM
|
Antiproliferative activity against human DU-145 cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Antiproliferative activity against human DU-145 cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
24994714 |
| PC-3 | IC50 |
5 μM
|
Antiproliferative activity against human PC-3 cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Antiproliferative activity against human PC-3 cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
24994714 |
In Vitro
OSU-53 directly activates recombinant AMPK α1β1γ2 protein with an IC50 of 0.3 μM[1].
OSU-53 (18 h) dose-dependently inhibits the migration of MDA-MB-231 and PC-3 cells, with effects independent of cell viability reduction[1].
OSU-53 (24 h) dose-dependently inhibits the invasion of MDA-MB-231 and PC-3 cells, with effects independent of cell viability reduction[1].
OSU-53 (9-16 days) dose-dependently inhibits the formation of invasive, stellate colonies by MDA-MB-231 and PC-3 cells in three-dimensional culture[1].
OSU-53 reduces F-actin stress fiber formation in MDA-MB-231 cells[1].
OSU-53 (1-5 μM; 18 h) activates AMPK in the murine MDSC cell line MSC-2, as shown by increased p-AMPK levels following 5 μM treatment for 18 hours, without changing total AMPK levels[2].
OSU-53 (5-10 μM; 72 h) inhibits the viability of MCF-7, MDA-MB-231, MDA-MB-468, 4T1, LNCaP, DU-145, and PC-3 cancer cell lines with IC50 values of 5 μM, 7.5 μM, 5 μM, 6 μM, 9 μM, 8 μM, and 5 μM respectively after 72 h of treatment, and has no antiproliferative effect on normal MECs and PrECs[1].
OSU-53 (2.5-10 μM) reverses the mesenchymal phenotype of MDA-MB-231, 4T1, PC-3, and MDA-MB-468 cells via AMPK activation, inducing increased expression of epithelial markers and decreased expression of mesenchymal markers at the mRNA and/or protein level[1].
OSU-53 (5 μM) induces Foxo3a binding to the FBE3 and FBE4 regions of the E-cadherin promoter in MDA-MB-468, PC-3, and MDA-MB-231 cells[1].
OSU-53 (5 μM; 24 h) promotes nuclear localization of Foxo3a and cytoplasmic sequestration of MDM2 in MDA-MB-231, 4T1, and PC-3 cells by suppressing Akt and IKKβ phosphorylation[1].
OSU-53 (5 μM; 12 h) increases Foxo3a protein stability by reducing MDM2-mediated ubiquitination in cancer cells, an effect blocked by ectopic MDM2 or constitutively active Akt expression[1].
OSU-53 (1-10 μM; 24-72 h) inhibits the proliferation of all tested human thyroid cancer cell lines in a dose-dependent manner, with greatest potency (GI50 1.63-4.51 μM) in lines with activating RAS or BRAFV600E mutations, and lower potency (GI50 5.90-7.26 μM) in FTC133 and TPC1 cells[3].
OSU-53 (5 μM; 6-72 h) activates AMPK, suppresses mTOR signaling, and modulates ERK and AKT activation in human ATC cell lines, with cell-specific differences based on RAS or BRAFV600E mutation status[3].
OSU-53 (1-10 μM; 6-72 h) activates AMPK in BCPAP and FTC133 human DTC cell lines, suppresses mTOR signaling in all three tested DTC lines, and modulates ERK and AKT activation in a cell-specific manner[3].
OSU-53 (1-10 μM; 24-72 h; 5 μM; 24-48 h) does not rely primarily on AMPK activation for induced growth inhibition or autophagy in BCPAP and FTC133 human DTC cell lines, though AMPK contributes partially to mTOR/p70S6K signaling suppression in these cells[3].
OSU-53 (0.01-15 μM; cell-free assay; 1-10 μM; 24 h) directly inhibits mTOR activity in a cell-free system (IC50 8.23 μM) and reduces mTOR phosphorylation in U-Hth-7 and Hth-104 human thyroid cancer cell lines[3].
OSU-53 (0.5-10 μM; 18 h, overnight) does not induce apoptosis in the murine MDSC cell line MSC-2 at concentrations of 0.5, 1, and 5 μM, but induces apoptosis at 10 μM[2].
OSU-53 (0.5-5 μM; 12 h pre-incubation plus 24 h LPS stimulation) reduces nitric oxide production in LPS-stimulated murine MDSC cell line MSC-2, with a 3-fold decrease observed at 5 μM treatment[2].
OSU-53 (0.5-5 μM; overnight) reduces migration of the murine MDSC cell line MSC-2 toward tumor cell-derived chemoattractants, with a significant decrease observed at 5 μM treatment[2].
OSU-53 (0.5-5 μM; 24 h) reduces secretion of pro-inflammatory cytokines in LPS-stimulated murine MDSC cell line MSC-2, with a 1.5-fold decrease in TNF-α and 2.9-fold decrease in IL-6 observed at 5 μM treatment[2].
OSU-53 (5 μM; 24-48 h) induces autophagy in human thyroid cancer cell lines with RAS or BRAFV600E mutations, but does not induce meaningful apoptosis in any of the tested lines[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7, MDA-MB-231, MDA-MB-468, 4T1, LNCaP, DU-145, PC-3, normal mammary epithelial cells (MECs), normal prostate epithelial cells (PrECs)
-
Concentration:5-10 μM
-
Incubation Time:72 h
-
Result:Inhibited viability of seven cancer cell lines with IC50 values of 5 μM, 7.5 μM, 5 μM, 6 μM, 9 μM, 8 μM, and 5 μM respectively after 72 h.
Exhibited no antiproliferative effect on normal MECs and PrECs.
-
Cell Line:murine MDSC cell line MSC-2
-
Concentration:0.5 μM, 1 μM, 5 μM, 10 μM
-
Incubation Time:18 h (0.5 μM, 1 μM, 5 μM); overnight (10 μM)
-
Result:Did not induce apoptosis in MSC-2 cells at concentrations up to 5 μM.
Caused a significant increase in apoptotic cells at the 10 μM concentration.
-
Cell Line:murine MDSC cell line MSC-2
-
Concentration:1 μM, 5 μM
-
Incubation Time:18 h
-
Result:Did not alter total AMPK protein levels in MSC-2 cells.
Induced an increase in phosphorylated AMPK (p-AMPK) levels at 5 μM.
-
Cell Line:murine MDSC cell line MSC-2
-
Concentration:0.5 μM, 1 μM, 5 μM
-
Incubation Time:overnight
-
Result:Caused a significant reduction in the number of MSC-2 cells migrating toward tumor cell supernatant at 5 μM compared to controls.
-
Cell Line:murine MDSC cell line MSC-2
-
Concentration:0.5 μM, 1 μM, 5 μM
-
Incubation Time:24 h
-
Result:Caused a 1.5-fold decrease in TNF-α levels at 5 μM in LPS-stimulated MSC-2 cells.
Caused a 2.9-fold decrease in IL-6 levels at 5 μM in LPS-stimulated MSC-2 cells.
-
Cell Line:C643, U-Hth-7, SW1736, Hth-104, FTC133, TPC1, BCPAP
-
Concentration:1 μM, 5 μM, 10 μM
-
Incubation Time:24 h; 48 h; 72 h
-
Result:Inhibited proliferation of all 7 thyroid cancer cell lines in a dose-dependent manner.
Reduced GI50 values to 1.63-4.51 μM in cell lines with activating RAS or BRAF V600E mutations.
Resulted in a GI50 of 5.90 μM in FTC133 (PTEN null) cells.
Resulted in a GI50 of 7.26 μM in TPC1 (RET/PTC1) cells.
Caused significantly less growth inhibition in FTC133 and TPC1 compared to BCPAP at 5 μM.
-
Cell Line:C643, U-Hth-7, SW1736, Hth-104
-
Concentration:5 μM
-
Incubation Time:6 h; 12 h; 24 h; 48 h; 72 h
-
Result:Induced time-dependent activation of AMPK (increased p-AMPK relative to total AMPK) in all four ATC cell lines.
Reached peak AMPK activation at 12 hours and declined by 48 hours in RAS mutant lines (C643, U-Hth-7).
Activated TSC2 (increased p-TSC2) in three of the four cell lines, with no appreciable increase in C643.
Suppressed mTOR signaling (decreased p-p70S6K and p-S6) across all four cell lines.
Suppressed ERK activation (decreased p-ERK) after 48 hours in BRAF V600E mutant lines (SW1736, Hth-104) but not consistently in RAS mutant lines.
Down-regulated AKT activation (decreased p-AKT) in C643, U-Hth-7, and SW1736, but not Hth-104.
-
Cell Line:BCPAP, FTC133, TPC1, Hth-104
-
Concentration:5 μM; 1, 2.5, 5, 7.5, 10 μM
-
Incubation Time:6 h; 12 h; 24 h; 48 h; 72 h (5 μM treatment); 24 h (Hth-104 dose-response); 48 h (FTC133, TPC1 dose-response)
-
Result:Induced time-dependent AMPK activation (increased p-AMPK) in BCPAP and FTC133, but not TPC1, with 5 μM treatment.
Suppressed p-p70S6K activation in all three DTC cell lines, with complete abolition of p-p70S6K in BCPAP after 6 hours.
Induced time-dependent inactivation of ERK (decreased p-ERK) in FTC133, with variable inactivation in BCPAP and TPC1.
Induced time-dependent inactivation of AKT (decreased p-AKT) in FTC133 and TPC1, but not BCPAP.
Caused modest dose-dependent AMPK activation in Hth-104 and FTC133, but not TPC1, with dose-response treatment.
Decreased p-p70S6K in all three cell lines with dose-response treatment.
-
Cell Line:C643, U-Hth-7, SW1736, Hth-104, BCPAP, FTC133, TPC1
-
Concentration:5 μM
-
Incubation Time:6 h; 12 h; 24 h; 48 h; 72 h
-
Result:Induced increased conversion of LC3 I to LC3 II (autophagy marker) in all BRAF V600E mutant lines (BCPAP, Hth-104, SW1736) and RAS mutant lines (C643, U-Hth-7).
Caused modest LC3 I/II conversion in TPC1 and absent conversion in FTC133.
Induced a slight increase in PARP cleavage (apoptosis marker) only in U-Hth-7 after 48 hours of treatment.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/cAnNCr (female, 5-7 weeks of age, syngeneic orthotopic breast cancer model via injection of 4T1 cells)[1]
-
Dosage:50 mg/kg; 100 mg/kg
-
Administration:p.o.; daily; 21 days
-
Result:Exhibited no changes in body weight.
Modestly inhibited primary tumor growth.
Dose-dependently increased phosphorylation of AMPK and ACC, reduced phosphorylation of Akt, and increased Foxo3a expression in tumor lysates.
Increased E-cadherin levels and decreased vimentin, YB-1, Snail, and Twist levels in tumor lysates.
Reduced the number and size of metastatic nodules on the lung surface relative to controls.
Chemical Information
-
CAS No. 1290069-19-0
-
Molecular Weight 583.60
-
Formula C25H24F3N3O6S2
-
SMILES
O=S(C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1)(NC2=CC=C(/C=C(SC(N3CC4(C)CCCCC4)=O)/C3=O)C=C2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)